In­tel­lia Ther­a­peu­tics saidit dis­cov­ered a com­mon link among the pa­tients who faced the high­est liv­er en­zyme el­e­va­tions af­ter re­ceiv­ing its CRISPR gene edit­ing treat­ment...

To broad­en its oph­thal­mol­o­gy port­fo­lio, Tar­sus Phar­ma­ceu­ti­cals is dish­ing out $450 mil­lion up­front to ac­quire Phase 3 biotech Alkeus Phar­ma­ceu­ti­cals, the com­pa­nies said Thurs­day morn­ing.

It's...

LifeM­ine Ther­a­peu­tics has hauled in $263 mil­lion across two ven­ture rounds as it seeks to test a po­ten­tial­ly safer, more con­ve­nient im­muno­sup­pres­sant in trans­plant pa­tients...